Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R\textsubscript{CHADS}\textsubscript{2} Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

We appreciate the comments and suggestions made by Apostolakis et al. As they point out, there are several important limitations of our analysis, including the high-risk nature of the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial cohort. Factors associated with stroke or systemic embolism in a selected high-risk population may not be generalizable to other patient populations, including patients not currently being treated with oral anticoagulation. It was for precisely these reasons that we validated our model in the independent and unselected ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort.

In our external validation analyses, we found that use of the R\textsubscript{CHADS}\textsubscript{2} score improved risk stratification in the ATRIA cohort. When compared with the CHADS\textsubscript{2} index, use of the R\textsubscript{CHADS}\textsubscript{2} resulted in 12% (95% confidence interval, 6% to 19.5%) net reclassification improvement in patients on warfarin. Net reclassification improvement was even more robust in those not receiving oral anticoagulation (net reclassification improvement in 12% (95% confidence interval, 6% to 19.5%) net reclassification in patients with atrial fibrillation should include renal function.

Although we certainly agree that additional validation is warranted, the data from ROCKET AF and ATRIA indicate that stroke risk stratification in patients with atrial fibrillation should include renal function.

Disclosures

Dr Piccini reports receiving research grants from Johnson & Johnson and Boston Scientific and serves as a consultant to Medtronic, Forest Laboratories, Sanofi Aventis, and Johnson & Johnson. Dr Singer is supported, in part, by the Eliot B. and Edith C. Shoolman fund of the Massachusetts General Hospital. He receives consulting fees from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Pfizer, and Sanofi. Dr Patel receives honoraria from Johnson & Johnson and Bayer and consulting fees from Ortho McNeil Janssen and Bayer HealthCare and serves on an advisory board for Genzyme. Dr Mahaffey receives research support from Bayer and Johnson & Johnson and consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company. Dr Mahaffey receives consulting fees from AstraZeneca and Johnson & Johnson, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company. Dr Mahaffey receives consulting fees from AstraZeneca and Johnson & Johnson, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company. Dr Mahaffey receives consulting fees from AstraZeneca and Johnson & Johnson, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plow (now Merck), and The Medicines Company.
References


Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts"


doi: 10.1161/CIRCULATIONAHA.113.004013

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/128/11/e172

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/